Home › Compare › BHCCF vs ABBV
BHCCF yields 546.75% · ABBV yields 3.06%● Live data
📍 BHCCF pulled ahead of the other in Year 1
Combined, BHCCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BHCCF + ABBV for your $10,000?
Benchmark Holdings plc, together with its subsidiaries, engages in the provision of technical services, products, and specialist knowledge that supports the development of food and farming industries. The company operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers sea bass/bream, salmon, shrimp, and tilapia breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry. The Health segment provides health products, including Ectosan Vet and CleanTreat medicinal sea lice solutions to the aquaculture market. The company operates in the United Kingdom, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, rest of the Europe, and internationally. Benchmark Holdings plc was founded in 2000 and is headquartered in Sheffield, the United Kingdom.
Full BHCCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.